MX169441B - Peptidos capaces de ser reconocidos por anticuerpos inducidos contra el retro-virus de inmunodeficiencia humana (hiv-virus) sus aplicaciones para diagnostico de infecciones causadas por alguno de estos virus y en su caso, para vacunas contra sida - Google Patents

Peptidos capaces de ser reconocidos por anticuerpos inducidos contra el retro-virus de inmunodeficiencia humana (hiv-virus) sus aplicaciones para diagnostico de infecciones causadas por alguno de estos virus y en su caso, para vacunas contra sida

Info

Publication number
MX169441B
MX169441B MX010385A MX1038588A MX169441B MX 169441 B MX169441 B MX 169441B MX 010385 A MX010385 A MX 010385A MX 1038588 A MX1038588 A MX 1038588A MX 169441 B MX169441 B MX 169441B
Authority
MX
Mexico
Prior art keywords
viruses
peptide
hiv
vaccines
peptides
Prior art date
Application number
MX010385A
Other languages
English (en)
Inventor
Francois Clavel
Pierre Sonigo
Mireille Guyader
Pierre Tiollais
Lisa Chakrabarti
Ronald Desrosiers
Marc Alizon
Luc Montagnier
Denise Guetard
Original Assignee
Pasteur Institut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR8701739A external-priority patent/FR2610632B1/fr
Priority claimed from FR8705398A external-priority patent/FR2614025B1/fr
Application filed by Pasteur Institut filed Critical Pasteur Institut
Publication of MX169441B publication Critical patent/MX169441B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/702—Specific hybridization probes for retroviruses
    • C12Q1/703—Viruses associated with AIDS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • G01N2333/16—HIV-1, HIV-2
    • G01N2333/162—HIV-1, HIV-2 env, e.g. gp160, gp110/120, gp41, V3, peptid T, DC4-Binding site
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • AIDS & HIV (AREA)
  • Public Health (AREA)
  • Analytical Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)

Abstract

La presente invención se refiere a procedimiento para la preparación de un peptido que tiene propiedades inmunológicas en común con las del esqueleto peptídico de la glicoproteína de envoltura de los viruos de la clase HIV-2, y que tiene igualmente una estrucutra peptídica en común con el esqueleto peptídico de la glicoproteína de SIV-1, caracterizado porque comprende las etapas siguientes: -condensar sucesivamente de a dos los aminoacilos sucesivos en el orden requerido, o aminoacilos y fragmentos previamente formados y que contienen ya varios aminoacilos en el orden apropiado, o bien varios fragmentos previamente preparados de esta manera, proteger previamente todas las funciones reactivas portadas por estos aminoacilos o fragmentos, con excepción de las funciones amina y carboxilo que deben intervenir en la formación de los enlaces peptídicos.
MX010385A 1987-02-11 1988-02-11 Peptidos capaces de ser reconocidos por anticuerpos inducidos contra el retro-virus de inmunodeficiencia humana (hiv-virus) sus aplicaciones para diagnostico de infecciones causadas por alguno de estos virus y en su caso, para vacunas contra sida MX169441B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR8701739A FR2610632B1 (fr) 1987-02-11 1987-02-11 Peptides caracteristiques des retrovirus d'immunodeficience humaine (virus hiv) leurs applications au diagnostic des infections dues a certains de ces virus et, le cas echeant, a la vaccination contre le sida
FR8705398A FR2614025B1 (fr) 1987-04-15 1987-04-15 Peptides susceptibles d'etre reconnus par des anticorps induits contre des retrovirus d'immunodeficience humaine (virus hiv) leurs applications au diagnostic des infections dues a certains de ces virus et, le cas echeant, a la vaccination contre le sida

Publications (1)

Publication Number Publication Date
MX169441B true MX169441B (es) 1993-07-05

Family

ID=26225771

Family Applications (1)

Application Number Title Priority Date Filing Date
MX010385A MX169441B (es) 1987-02-11 1988-02-11 Peptidos capaces de ser reconocidos por anticuerpos inducidos contra el retro-virus de inmunodeficiencia humana (hiv-virus) sus aplicaciones para diagnostico de infecciones causadas por alguno de estos virus y en su caso, para vacunas contra sida

Country Status (9)

Country Link
EP (1) EP0750041B1 (es)
KR (1) KR0135885B1 (es)
AT (1) ATE417108T1 (es)
CA (2) CA1341634C (es)
DE (1) DE3856595D1 (es)
IE (1) IE990955A1 (es)
MX (1) MX169441B (es)
NZ (1) NZ223494A (es)
OA (1) OA08716A (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60132924T2 (de) 2000-10-23 2009-03-05 Gen-Probe Inc., San Diego Zusammensetzungen und methoden zur detektion von humanem immundefizienz virus 2 (hiv-2)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0239425B1 (fr) * 1986-01-22 1989-11-02 Institut Pasteur Rétrovirus du type HIV-2 susceptible de provoquer le SIDA, et ses constituants antigéniques et nucléiques
EP0269520A3 (fr) * 1986-11-21 1988-08-24 Institut Pasteur Rétrovirus du type HIV-2 susceptible de provoquer le sida, et ses constituants antigéniques et nucléiques

Also Published As

Publication number Publication date
KR0135885B1 (ko) 1998-04-25
CA1341520C (fr) 2007-01-30
IE990955A1 (en) 2000-12-13
DE3856595D1 (de) 2009-01-22
EP0750041A2 (fr) 1996-12-27
NZ223494A (en) 1991-06-25
EP0750041B1 (fr) 2008-12-10
ATE417108T1 (de) 2008-12-15
CA1341634C (en) 2013-03-19
EP0750041A3 (fr) 1997-01-22
KR890700603A (ko) 1989-04-26
OA08716A (fr) 1989-03-31

Similar Documents

Publication Publication Date Title
MY136081A (en) Modified hiv - 1gag p17 peptide and immunogenic composition
DK1159298T3 (da) HIV-peptider, antigener og vaccinekompositioner
ES2194836T3 (es) Peptidos para su uso en vacunacion e induccion de anticuerpos neutralizantes contra el virus de la inmunodeficiencia humana.
MY103182A (en) Vaccines against acquired immune deficiency syndrome.
ES2104556T3 (es) Peptidos que tienen propiedades inmunologicas de hiv-2.
ES2066887T3 (es) Anticuerpo monoclonal para diferenciar individuos seropositivos hiv-2 de los hiv-1.
ES2127294T3 (es) Vacunas del virus de la inmunodeficiencia anti-felino (fiv).
DE3855134D1 (de) Monoklonale menschliche antikörper gegen hiv-i
ES2118939T3 (es) Peptido para el diagnostico e inmunizacion contra la infeccion con t.cruzi.
DE68925660D1 (de) Peptidfragmente von HIV
MX169441B (es) Peptidos capaces de ser reconocidos por anticuerpos inducidos contra el retro-virus de inmunodeficiencia humana (hiv-virus) sus aplicaciones para diagnostico de infecciones causadas por alguno de estos virus y en su caso, para vacunas contra sida
ES2044976T3 (es) Preparados activos frente a infecciones por pseudomonas aeruginosa y procedimiento para su fabricacion.
SE8701628D0 (sv) Medel for analys mm
DK0412766T3 (da) Peptidfragmenter af HIV
DK0707473T3 (da) Orale farmaceutiske præparater omfattende et protein eller et peptid, et antistof og polymerkugler
ES2097207T3 (es) Receptor de poli-ig de sintesis, complejos receptor-anticuerpo, produccion y aplicacion de los mismos.
ES2118720T3 (es) Produccion y utilizacion de agentes antihelminticos e inmunogenos protectores.
FI95871B (fi) Menetelmä HIV-hiukkasimmunogeenin ja sen vasta-aineen valmistamiseksi
PT99791A (pt) Processo para a preparacao de peptidos seleccionados do antigene especifico de grupo (gas) do virus da imunodeficiencia humana (hiv) e de composicoes farmaceu-ticas que os contem
ES2052273T3 (es) Composicion que contiene un epitopo b de la glicoproteina que envuelve un retrovirus y un epitopo t de una proteina distinta de dicho retrovirus.
DK0472706T3 (da) Induktion af beskyttelse mod viral infektion
ATE256745T1 (de) Therapeutischer- und präventivimpfstoff gegen hiv
GB1413401A (en) Influenza vaccine
RU93004854A (ru) Пептиды для вакцинации и индукции нейтрализующих антител против вируса иммунодефицита человека
TH87273A (th) วัคซีน